Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+50 28-DAY vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Norethindrone is primarily metabolized via reduction to dihydro metabolites and glucuronide conjugation, with minor involvement of CYP3A4. Ethinyl estradiol is primarily metabolized by CYP3A4, with extensive first-pass metabolism and conjugation (sulfation and glucuronidation).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norethindrone: ~80% bound to albumin and SHBG; Ethinyl estradiol: ~97% bound to albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~15 L/kg, indicating extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: Norethindrone ~64%; Ethinyl estradiol ~40-50% (due to first-pass metabolism).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dosage adjustment is required for mild to moderate renal impairment. Use is contraindicated in patients with end-stage renal disease or on dialysis due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with acute hepatitis, hepatic cirrhosis, or liver tumors (benign or malignant). For Child-Pugh Class A, use with caution; Class B or C: contraindicated due to impaired metabolism and risk of cholestasis.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for use before menarche. For post-menarchal adolescents, dosing is the same as adults (one tablet daily). Safety and efficacy have not been established in prepubertal children.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women due to lack of efficacy and increased cardiovascular risks. If used off-label, monitor for thromboembolism, hypertension, and hepatic effects.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age, particularly in women over 35 years, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic events,Elevated risk of myocardial infarction and stroke especially in smokers >35,Hepatic neoplasia (benign and malignant) reported,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism alterations,Headache including migraine exacerbation,Uterine bleeding irregularities,Possible depression,Reduced efficacy with certain drugs such as enzyme inducers
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Known or suspected pregnancy,Current or history of venous thromboembolism,Current or history of arterial thrombotic disease,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Hepatic impairment or active liver disease,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Cigarette smoking in women >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food interactions. Grapefruit juice may increase estrogen levels (possible increased risk of side effects); avoid excessive consumption. Maintain consistent diet with regard to vitamin C intake as high doses may enhance estrogen absorption.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Contraindicated in pregnancy. Category X: Use in first trimester has been associated with congenital defects including cardiovascular and limb defects. Exposure in second and third trimesters may cause fetal harm including masculinization of female fetuses due to androgenic progestin (norethindrone). Discontinue immediately if pregnancy occurs.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Small amounts of norethindrone and ethinyl estradiol are excreted in breast milk (M/P ratio for norethindrone ~0.6; ethinyl estradiol ~0.1). May reduce milk quantity and quality. Not recommended for breastfeeding mothers; consider alternative contraception.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustment applicable; drug contraindicated during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant as therapy must be stopped. If accidental exposure, discontinue immediately and evaluate fetal risk.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
NORINYL 1+50 28-DAY (norethindrone 1 mg / mestranol 50 mcg) is a first-generation combined oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Use with caution in patients with migraine with aura. Breakthrough bleeding may occur; if persistent, rule out pregnancy or consider a pill with higher estrogen or different progestin. Missed pill protocol: if one pill missed, take it as soon as remembered; if two pills missed, take two pills for two days and use backup contraception for 7 days.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time each day. If you miss a pill, follow the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills or start a new pack late.,This medication does not protect against sexually transmitted infections (STIs).,Avoid smoking while taking this medication, especially if you are over 35 years old, as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider if you experience severe headaches, chest pain, leg pain or swelling, vision changes, or jaundice.,If you experience persistent breakthrough bleeding, consult your healthcare provider.,Do not take this medication if you are pregnant or think you may be pregnant.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+50 28-DAY vs ALTAVERA, answered by our medical review team.
NORINYL 1+50 28-DAY is a Oral Contraceptive that works by Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+50 28-DAY and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+50 28-DAY is: One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+50 28-DAY and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+50 28-DAY is classified as Category C. Contraindicated in pregnancy. Category X: Use in first trimester has been associated with congenital defects including cardiovascular and limb defects. Exposure in second and third. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.